15 research outputs found
Ferritic stainless steel welding with the A-TIG process
O processo de soldagem TIG com fluxo (processo A-TIG) apresenta como principal vantagem a possibilidade de se obter uma maior penetração do cordão de solda empregando os mesmos parâmetros de soldagem do processo TIG convencional. Diversos estudos mostram a influência dos fluxos ativos sobre as características geométricas das soldas em aços inoxidáveis austeníticos, porém pouco se sabe sobre a influência deste processo nas características geométricas e metalúrgicas de cordões de solda em aços inoxidáveis ferríticos. Neste trabalho são aplicados diferentes tipos de fluxo na soldagem de aço inoxidável ferrítico com o objetivo de verificar possíveis influências no perfil do cordão de solda, no seu aspecto visual, na microestrutura, na dureza da zona fundida e na resistência ao impacto (ensaio Charpy). As soldagens "bead-on-plate" foram realizadas sem metal de adição. Foram utilizados seis tipos de fluxo, sendo um óxido elaborado em laboratório (TiO2) e cinco fluxos comerciais. Os resultados mostraram que a utilização do fluxo permite um aumento na penetração com mudanças significativas no aspecto do cordão de solda. Verificou-se ainda que a microestrutura e a dureza do cordão de solda do aço estudado não foram afetadas pelo tipo de fluxo utilizado, com a microestrutura analisada em microscópio óptico. O aço em estudo mostrou um alto grau de fragilidade à temperatura ambiente._________________________________________________________________________________________ RESUMO: The A-TIG welding process presents as main advantage the possibility of increase in the penetration depth using the same parameters as conventional TIG welding. Many researchers show the influence of the active flux on the weld geometry in austenitic stainless steel, however little it is known of the influence of this process in the weld fillet shape and metallurgic characteristics of the weld fillet in ferritic stainless steel. In this work different types of flux are applied with the objective to verify possible influences on the weld fillet in ferritic stainless steel welding, such its visual aspect, the microstructure, the hardness and resistance to the impact of the fusion zone. Bead on plate welds were made without metal filler. Six types of flux had been used, and one flux was prepared in laboratory (TiO2) and the others five were commercial flux. The results indicate that the use of the flux allows increase in the penetration with significant changes in the aspect of the weld fillet. It was verified that the microstructure and the hardness of the weld fillet of this ferritic stainless steel was not been affected by the flux type. The result of the Charpy test in the metal base it was batter in the fusion zone
Recommended from our members
Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial
Background
Optimal secondary prevention antithrombotic therapy for patients with antiphospholipid syndrome (APS)-associated ischemic stroke, transient ischemic attack, or other ischemic brain injury is undefined. The standard of care, warfarin or other vitamin K antagonists at standard or high intensity (international normalized ratio (INR) target range 2.0-3.0/3.0-4.0, respectively), has well-recognized limitations. Direct oral anticoagulants have several advantages over warfarin, and the potential role of high-dose direct oral anticoagulants vs high-intensity warfarin in this setting merits investigation.
Objectives
The Rivaroxaban for Stroke patients with APS trial (RISAPS) seeks to determine whether high-dose rivaroxaban could represent a safe and effective alternative to high-intensity warfarin in adult patients with APS and previous ischemic stroke, transient ischemic attack, or other ischemic brain manifestations.
Methods
This phase IIb prospective, randomized, controlled, noninferiority, open-label, proof-of-principle trial compares rivaroxaban 15 mg twice daily vs warfarin, target INR range 3.0-4.0. The sample size target is 40 participants. Triple antiphospholipid antibody-positive patients are excluded. The primary efficacy outcome is the rate of change in brain white matter hyperintensity volume on magnetic resonance imaging, a surrogate marker of presumed ischemic damage, between baseline and 24 months follow-up. Secondary outcomes include additional neuroradiological and clinical measures of efficacy and safety. Exploratory outcomes include high-dose rivaroxaban pharmacokinetic modeling.
Conclusion
Should RISAPS demonstrate noninferior efficacy and safety of high-dose rivaroxaban in this APS subgroup, it could justify larger prospective randomized controlled trials